Livedoid vasculitis
Livedoid vasculitis ndi matenda osatha akhungu omwe amawonedwa makamaka mwa amayi achichepere mpaka azaka zapakati. Mawu amodzi omwe amagwiritsidwa ntchito pofotokoza mawonekedwe ake ndi "Zilonda zowawa za purpuric zokhala ndi mawonekedwe a reticular kumunsi kwa malekezero" (PURPLE). Iwo amagwirizana ndi angapo matenda, kuphatikizapo aakulu venous matenda oopsa ndi varicosities.
☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
Ikhoza kutsagana ndi ululu.
References
Livedoid vasculopathy ndi khungu losowa kwambiri lomwe limadziwika ndi zilonda zowawa zomwe zimabwereranso kumunsi kwa miyendo.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy ndizovuta zapakhungu zomwe zimayambitsa zilonda zam'munsi zomwe zimangotsala pang'ono kusiya zipsera zotuwa zomwe zimatchedwa atrophie blanche. Ngakhale kuti chifukwa chenicheni sichikudziwikabe, akukhulupirira kuti kuchuluka kwa magazi kuundana (hypercoagulability) ndiye chinthu chachikulu, pomwe kutupa kumakhala gawo lachiwiri. Zomwe zimapangitsa kuti magazi aziundana ndi izi: deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Mu biopsies, matendawa amawonetsa kutsekeka kwa magazi mkati mwa zotengera, kukhuthala kwa makoma a zotengera, ndi zipsera. Kuchiza kumaphatikizapo njira zingapo zomwe zimayang'ana kwambiri kuteteza magazi kuundana ndi mankhwala monga anti-platelet mankhwala, ochepetsa magazi, ndi fibrinolytic therapy. Mankhwala osiyanasiyana angagwiritsidwe ntchito pakhungu ili - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy ndizovuta kwambiri pomwe zotupa zimachitika pamiyendo yonse. Mapangidwe a magazi m'mitsempha yaing'ono yamagazi amaganiziridwa kuti amayamba chifukwa cha kuwonjezeka kwa magazi ndi kuchepa kwa magazi, komanso kuwonongeka kwa chotengeracho. Ndikofala kwambiri mwa akazi, makamaka azaka zapakati pa 15 ndi 50. Kusiya kusuta, kusamalira zilonda, ndi kugwiritsa ntchito mankhwala monga ochepetsa magazi ndi antiplatelet mankhwala akhala akugwira ntchito.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
